Entry into a Material Definitive Agreement. On August 31, 2026, Intelligent Bio Solutions Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with a single institutional investor for the sale by the Company of (i) 2,036,659 shares (the “Shares”) of the Company’s common stock (or Series M Pre-funded warrants in lieu thereof (the “Pre-Funded Warrants”)), par value $0.01 per share (the “Common Stock”), (ii) Series N-1 warrants to purchase up to an aggrega…

Unregistered Sales of Equity Securities. The information contained above in

Results of Operations and Financial Condition. On August 19, 2026, Intelligent Bio Solutions Inc. (the “Company”) issued a press release (the “Press Release”) announcing financial results for the three months and full fiscal year ended June 30, 2026. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished in this Current Report on Form 8-K under Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for pur…

Results of Operations and Financial Condition. On May 13, 2026, Intelligent Bio Solutions Inc. (the “Company”), issued a press release (the “Press Release”) announcing financial results for the fiscal quarter ended March 31, 2026. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished in this Current Report on Form 8-K under Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18…

Other Events Awards to Directors On the Grant Date, the Committee also approved time-vesting restricted stock awards to non-employee directors, with an aggregate of 20,000 shares granted under the Plan pursuant to the applicable U.S. Director 2026 Restricted Stock Award Agreement form and AUS/UK Director 2026 Restricted Stock Award Agreement form, vesting on the 12-month anniversary of the Grant Date, subject to each director’s continued service on the Board through the vesting date; all such…

The filing details the grant of restricted stock awards to executives, which is a routine compensation matter.

Results of Operations and Financial Condition. On February 12, 2026, Intelligent Bio Solutions Inc. (the “Company”), issued a press release (the “Press Release”) announcing financial results for the fiscal quarter ended December 31, 2025. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained herein and in the accompanying exhibits shall not be incorporated by reference into any filing of the Company, whether made before or after…

Results of Operations and Financial Condition. On February 5, 2026, Intelligent Bio Solutions Inc. (the “Company”), issued a press release (the “Press Release”) announcing preliminary, unaudited revenue results for the fiscal second quarter ended December 31, 2025. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained herein and in the accompanying exhibits shall not be incorporated by reference into any filing of the Company, w…

Entry into a Material Definitive Agreement. On December 31, 2025, Intelligent Bio Solutions Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with two healthcare focused institutional investors for the sale by the Company of (i) 2,298,850 shares (the “Shares”) of the Company’s common stock (or Series L Pre-funded warrants in lieu thereof (the “Pre-Funded Warrants”)), par value $0.01 per share (the “Common Stock”), (ii) Series K-1 warrants to purchase…

Unregistered Sales of Equity Securities. The information contained above in

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On December 15, 2025, Intelligent Bio Solutions Inc. (the “Company”) received a deficiency letter from the Nasdaq Listing Qualifications Department (the “Staff”) notifying the Company that because the closing bid price for the Company’s common stock was below $1.00 per share for the last 30 consecutive business days, the Company did not meet the $1.00 per share minimum bid price requirement fo…

Material Modifications of Rights of Security Holders. To the extent required by

Unregistered Sales of Equity Securities. On November 25, 2025, the Board of Directors of Intelligent Bio Solutions Inc. (the “Company”) approved the issuance of 75,000 restricted shares of Company common stock, par value $0.01 per share, to MDM Worldwide Solutions, Inc. (“MDM”) as equity compensation in connection with the Company’s engagement of MDM to provide strategic communication advisory and consulting services pursuant to an engagement letter effective as of September 11, 2025. The equ…

Results of Operations and Financial Condition. On November 12, 2025, Intelligent Bio Solutions Inc. (the “Company”), issued a press release (the “Press Release”) announcing financial results for the fiscal quarter ended September 30, 2025. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained herein and in the accompanying exhibits shall not be incorporated by reference into any filing of the Company, whether made before or afte…

Results of Operations and Financial Condition. On November 4, 2025, Intelligent Bio Solutions Inc. (the “Company”), issued a press release (the “Press Release”) announcing preliminary, unaudited revenue results for the fiscal first quarter ended September 30, 2025. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained herein and in the accompanying exhibits shall not be incorporated by reference into any filing of the Company, w…

The filing is about an amendment to the company's long-term incentive plan, not a management change.

Results of Operations and Financial Condition. On August 15, 2025, Intelligent Bio Solutions Inc. (the “Company”) issued a press release (the “Press Release”) announcing financial results for the three months and full fiscal year ended June 30, 2025. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained herein and in the accompanying exhibits shall not be incorporated by reference into any filing of the Company, whether made bef…

Results of Operations and Financial Condition. On August 7, 2025, Intelligent Bio Solutions Inc. (the “Company”), issued a press release (the “Press Release”) announcing preliminary, unaudited revenue results for the fiscal fourth quarter ended June 30, 2025. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained herein and in the accompanying exhibits shall not be incorporated by reference into any filing of the Company, whether…

Entry into a Material Definitive Agreement. Inducement Agreements On July 25, 2025, Intelligent Bio Solutions Inc. (the “Company”) entered into warrant exercise inducement offer letters (each an “Inducement Agreement”) with certain existing holders of certain Company warrants (collectively, the “Holders”) to: (i) receive new warrants (the “Inducement Warrants” or “Series J Warrants”) to purchase up to a number of shares of the Company’s common stock equal to 200% of the number of warrant shar…

Unregistered Sales of Equity Securities The information set forth in

The company amended employment agreements and increased salaries for the CEO and CFO.

The filing is about an amendment to the company's long-term incentive plan and does not involve any management changes.

Results of Operations and Financial Condition. On May 13, 2025, Intelligent Bio Solutions Inc. (the “Company”), issued a press release (the “Press Release”) announcing financial results for the fiscal quarter ended March 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for pur…

Entry into a Material Definitive Agreement. On February 20, 2025, Intelligent Bio Solutions Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Ladenburg Thalmann & Co. Inc., as representative (the “Representative”) of the underwriters named in Schedule I thereto (collectively, the “Underwriters”), relating to an underwritten public offering of 1,304,348 shares (the “Base Shares”) of the Company’s common stock, $0.01 par value per share (the “Common…

by reference. The Representative Warrants and shares issuable upon exercise of the Representative Warrants have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or the securities laws of any state, and are being offered and sold in reliance on the exemption from registration under the Securities Act, afforded by Section 4(a)(2) and/or Rule 506 promulgated thereunder.